NIH clinical trials Ovarian Cancer
- Blocking DNA Repair in Advanced BRCA-Mutated Cancer
(Posted: ) - In this trial, patients with relapsed or refractory advanced cancer and confirmed BRCA mutations who have not previously been treated with a PARP inhibitor will be given BMN 673 by mouth once a day in 28-day cycles.
- Experimental Drug for Relapsed or Resistant Ovarian Cancer
(Posted: ) - In this trial, women with metastatic or unresectable epithelial ovarian, fallopian tube, or primary peritoneal cancer that has recurred after, or has not responded to, previous therapies will receive the experimental drug birinapant.
- Genetically Engineered Immunotherapy for Advanced Cancer
(Posted: ) - In this trial, doctors will collect T lymphocytes from the blood of patients with advanced mesothelin-expressing cancer and genetically engineer these cells to recognize mesothelin. The gene-engineered cells will then be multiplied and infused into the patients to fight their cancer.
- Sequencing Treatment with a PARP Inhibitor and Chemotherapy
(Posted: ) - In this clinical trial, patients will be treated in 21-day cycles, with the first cycle being either intravenous carboplatin on day 1 followed by 7 days of oral olaparib or oral olaparib for 7 days followed by intravenous carboplatin on day 8. In the second cycle, the treatment assignments will be reversed.
- Testing Dose-Dense Paclitaxel for Ovarian and Related Cancers
(Posted: ) - In this trial, women with stage III or IV ovarian epithelial, fallopian tube, or primary peritoneal cancer will be randomly assigned to receive either standard or dose-dense paclitaxel in addition to standard carboplatin (given once every 3 weeks) and optional bevacizumab.
You might also like
Call to step up the pace of TB-HIV collaborative activities — Weekly Blitz
Discovery by biomedical research of new and improved interventions can get into the bucket of implementation.